I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Filing Receipt Corrections, Office of Initial Patent Examination, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the

date shown bell control of the shown bell co

12)25(04 Signature: Sam Walikowy Lies i Malikouzakis)

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of: Kohei MIYAZONO et al.

Application No.: 10/630,555

Group Art Unit: 1623

Filed: July 30, 2003

Examiner: Not Yet Assigned

For: ANTIBODIES WHICH BIND SPECIFICALLY TO

**ACTIVIN RECEPTOR LIKE KINASES** 

### REQUEST FOR CORRECTED FILING RECEIPT

Filing Receipt Corrections
Office of Initial Patent Examination
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby requests that a corrected Filing Receipt be issued in the above-identified application. The official Filing Receipt received by Applicant, a copy of which is attached hereto, has the following error:

In the Foreign Applications section, please change the sixth foreign application number to -- 9316099.2 --.

Please refer to the copy of the filing receipt, wherein the change is indicated. Applicants are also attaching a copy of the cover page of the international priority application wherein the correct foreign application number is listed.

Applicant additionally requests that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect this correction.

Applicant believes no fee is due with this request. However, if a fee is due, please charge our Deposit Account No. 50-0624, under Order No. **LUD 5298.5 DIV (10309270)** from which the undersigned is authorized to draw.

Respectfully submitted,

666 Fifth Avenue New York, New York (212) 318-3000

(212) 318-3400 (fax)

Norman D. Hanson

Registration No.: 30,946

FULBRIGHT & JAWORSKI L.L.P.

Attorney for Applicant



### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademurk Office Address COMMISSIONER FOR PATENTS O. Dox 1450 Alexandrin, Vignus 22313-1450 www.uspit.gov

FILING OR 371 TOT CLMS IND CLMS DRAWINGS ART UNIT FIL FEE REC'D ATTY.DOCKET NO APPL NO. (c) DATE 2 NY-LUD 5298.5-DIV-US 11 1 10/630,555 07/30/2003 750 1623

**CONFIRMATION NO. 7477** 

024972 FULBRIGHT & JAWORSKI, LLP 666 FIFTH AVE NEW YORK, NY 10103-3198

**FILING RECEIPT** 

OC000000011486524\*

Date Mailed: 12/15/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

### Applicant(s)

Kohei Miyazono, Uppsala, SWEDEN; Peter Ten Dijke, Uppsala, SWEDEN; Petra Franzen, Uppsala, SWEDEN; Hidetoshi Yamashita, Uppsala, SWEDEN; Carl-Henrik Heldin, Uppsala, SWEDEN;

### Domestic Priority data as claimed by applicant

This application is a DIV of 09/903,068 07/11/2001 which is a DIV of 09/679 187 10/03/2000 PAT 6,331,621. which is a DIV of 08/436,265 10/30/1995 PAT 6,316,217 which is a 371 of PCT/GB93/02367 11/17/1993

### Foreign Applications

UNITED KINGDOM 9224057.1 11/17/1992 UNITED KINGDOM 9304677.9 03/08/1993 UNITED KINGDOM 9304680.3 03/08/1993 UNITED KINGDOM 9311047.6 05/28/1993 UNITED KINGDOM 9313763.6 07/02/1993 UNITED KINGDOM 9136099.2 08/03/1993---UNITED KINGDOM 9321344.5 10/15/1993

931099231

If Required, Foreign Filing License Granted: 12/12/2003

Projected Publication Date: 03/25/2004

Non-Publication Request: No

Early Publication Request: No

Title

Antibodies which bind specifically to activin receptor like kinases

**Preliminary Class** 

435

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

	(51) International Patent Classifi C12N 15/12, C07K-13/ C12N 5/10, A61K 37/0	<del>9</del> 0 ·	A2	i	) International Publication Number:	WO 94/11502 26 May 1994 (26.05.94)
	9304677.9 8 9304680.3 8 9311047.6 2 9313763.6 2 9316099.2 3	17 November 1993 7 November 1992 (17.1 March 1993 (08.03.93) March 1993 (08.03.93) 8 May 1993 (28.05.93) July 1993 (02.07.93) August 1993 (03.08.93 5 October 1993 (15.10.	(17.11. (17.11. (17.92) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1	GB GB GB GB GB GB GB GB	(81) Designated States: AU, CA, JP, patent (AT, BE, CH, DE, DK, LU, MC, NL, PT, SE).	S-752 63 Uppsala (SE). Flogstavägen 25C, S-752 l, Petra [SE/SE]; Lindsala (SE). YAMASHITA, en 33A, S-752 63 Uppsala SE/SE]; Hesselmans väg ERY; Broadgate House, 7 LH (GB).
-	dington, London W2 11	PG (GB).			Published Without international search reg upon receipt of that report.	port and to be republished

(54) Title: ACTIVIN RECEPTOR-LIKE KINASES, PROTEINS HAVING SERINE THREONINE KINASE DOMAINS AND THEIR USE

```
C T G V
CODS . 22
micfer-II Ldiluckerfaevytaxilkoniseofetvavkifpydhyaswæredifsdinlikhenilof
         LLETKARGREGCYMAAQLEN-----DPVAVKI KPLODKOSWOSERET FSTPOHKHERILLOP
mActR-IIB
         LLEVKARGREGGWANGLLH-----ETVAVKIFFIQDKQSWQNEYEVYSIFQ:GKENLLQF
EACER-II
          L-rikvosgrfonvskodyrg------eavavkvtnolidepafnkeiei fettogløhføvlry
def-1
                                         II
                                                   III
                                                                  IV
arismobdus
                 I
htgfbr-II Ltaetratelgkgtklitafhakgrigetlitrhviskedlrnvgsslarglehlhsdhtp-C
BACCR-IIB IAAECRGSHLEVELMLITAFHDKGSLIDYLKGHIITWHELCHVAETHSRGISYLHEDVFMCR
          IGAERGTSVDVDURLITAFHERGSLSDFLKANVVSWNELCHIAETHARGLAYLHEDIRGLA
mactr-II
          ICSDXVDTCFVTELMLVIETHPSCSLHDFLLENTVNIETYYNLARSTASCLAFLHNQIGGSK
daf-1
subdomains
                     DLX M
CORE. MA
htgfbr-II -GRPX-PIVMRDLXSSHILVXXDLTCCLCDFGLSLRL---GPYSSVDDLANSGQVGTARYMAP
MACER-IIB GEGHAPSIAHRDFKSDVLLKSDLTAVLADFGLAVRF...EPGKPPGD..THGQVGTRRYHAP
          -DCHEPALSHEDIKSTHVLLENNUTACIADFCLALKF---BAGKSAGD--THGQVGTRRYHAP
BACER-II
           · ESHTPANAURDIKSTRIMTROLITCAI COLGLELSKPEDAASDIIAN · · ENYKOGTVRYLAP
daf -1
                                          VII
                                                                 VIII
subdomains
                VI -B
```

### (57) Abstract

A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-\(\beta\)-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence in subdomain VIII.